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Dengue virus (DENV) is the most important arbovirus worldwide, causing infections in
endemic countries and returning travellers from these areas. Rapid diagnostic tests are
needed to improve patient management and monitor local transmission. The detection of
DENV non-structural protein 1 (NS1) is a useful tool for the diagnosis, but the currently avail-
able methods can be time consuming or lack sensitivity. The objective of our study was to
evaluate a new rapid and semi-quantitative microfluidic DENV NS1 immuno-magnetic
agglutination assay based on aggregation of magnetic nanoparticles detected by an elec-
tronic reader (Virotrack Dengue Acute and Blubox, Blusense diagnostics, Copenhagen,
Denmark).
Methodology/Principal findings
A panel of 135 serum samples from travelers returning from dengue endemic countries was
analyzed (74 DENV positive samples including the four DENV serotypes, 26 Zika virus posi-
tive samples, 25 chikungunya virus positive samples, 5 malaria positive samples and 5 neg-
ative samples). Samples were tested by three different antigen detection methods: SD
Dengue NS1 Ag ELISA, SD BIOLINE Dengue Duo and ViroTrack Dengue Acute. The sensi-
tivity observed for SD Dengue NS1 Ag ELISA, ViroTrack Dengue Acute and SD BIOLINE
Dengue Duo was 97.2%, 91.1% and 68.1%, respectively. All methods showed high specific-
ity (98.4% for ViroTrack Dengue Acute and 100% for both SD Dengue NS1 Ag ELISA and
SD BIOLINE Dengue Duo). SD Dengue NS1 Ag ELISA and ViroTrack Dengue Acute only
failed to detect samples positive for DENV-2.
Conclusions/Significance
ViroTrack Dengue Acute is a sensitive and specific assay for DENV NS1 detection. It pro-
vides faster results than the ELISA method and a better performance than the rapid
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Author summary
Dengue virus is a human pathogen that causes millions of infections each year. It can be
found in nearly all tropical areas, and people living in those regions and travelers who visit
them are at risk of disease. The symptoms may vary from a mild flu-like disease to severe
hemorrhagic symptoms. Accurate diagnosis of dengue is important for a better manage-
ment of the disease and for epidemiological surveillance. Detection of DENV antigen is a
useful tool to diagnose DENV infections. However, currently available techniques are not
rapid (ELISA assays) or not accurate enough (immunochromatographic tests). Here, we
evaluate a new antigen detection technique based on aggregation of magnetic nanoparti-
cles. The method combines a short time to results (12 minutes) with a high diagnostic per-
formance. We therefore conclude that this new technique could be a useful tool for the
diagnosis of dengue.
Introduction
Dengue virus (DENV) (genus Flavivirus, family Flaviviridae) is mainly transmitted by the
bites of infected Aedes mosquitoes, and there are four different serotypes of the virus (DENV-
1, DENV-2, DENV-3 and DENV-4). Infection by one of the DENV serotypes does not induce
protection against other serotypes, and secondary infections are associated with a higher risk
of severe clinical disease [1] [2]. DENV infection has a large spectrum of clinical manifesta-
tions; from asymptomatic infections to a febrile illness (dengue fever) and in a minority of
cases a severe life-threatening disease [3]. DENV is considered the most important arthropod
borne virus (arbovirus) and the fastest growing vector borne disease worldwide [3]. It is esti-
mated that 390 millions of infections by DENV may occur annually, being 96 millions of them
symptomatic [4]. Most of the cases of DENV infection occur in endemic countries. The num-
ber of travelers returning from endemic countries is also increasing, and therefore DENV
infection has become a common diagnosis among travelers presenting fever at their return[5].
In a surveillance study in returning travelers from 2007 to 2011, DENV infection accounted
for 15% of the etiologies of febrile illness[6].
Laboratory diagnosis of DENV infection can be achieved by direct and indirect methods.
Direct methods include detection of the viral genome by reverse-transcription polymerase
chain reaction (RT-PCR), virus isolation or detection of viral antigens. Indirect diagnosis is
based on detection of immunoglobulin (Ig) M and IgG antibodies, and the confirmation by
indirect methods is achieved by the observation of seroconversion in paired acute and conva-
lescent serum samples[3]. The detection of non-structural protein 1 (NS1) of DENV, a glyco-
protein secreted from infected cells, is a useful tool for the diagnosis of acute DENV infection.
NS1 antigen can be detected by enzyme-linked immunosorbent assays (ELISA) or immuno-
chromatographic assays (ICT). Enzyme-linked immunosorbent assays have proven to be a
useful tool for NS1 antigen detection, with sensitivity values between 57.7%-95.1% according
to different studies[7][8][9][10][11]. However, the ELISA time to results (around 2-3h) and
the need for certain laboratory expertise to perform them make them not the best choice for
rapid diagnosis. Immunochromatographic tests, on the contrary, are easy to use and provide
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results in minutes. However, they offer a lower diagnostic performance, with sensitivities rang-
ing from 40% to 79.1% among different reports [9][11]. The specificity observed for both tech-
niques is very high (95%-100%)[7][8][10][11], and therefore a positive NS1 detection
represents a laboratory confirmed case of DENV infection (https://ecdc.europa.eu/en/
surveillance-and-disease-data/eu-case-definitions).
Immuno-magnetic agglutination (IMA) assays are newly developed methods that use mag-
netic particles coated with capture molecules (e.g. antibodies, ligands, nucleotides) that bind
specifically to the target biomarker, forming clusters that enable the detection. Different assays
have been developed for the detection of pathogens, small molecules and proteins[12]. These
methods are easy to use and can improve the sensitivity and time to the results of classic meth-
ods such as ELISAs [13]. An assay to detect DENV NS1 antigen has been developed based on
IMA technology[14].
A rapid and reliable diagnostic test for acute DENV infections would contribute to a better
patient management and would be helpful for surveillance programs in order to monitor local
virus transmission in non-endemic areas where the vectors are present. The objective of our
study was to evaluate a new rapid and semi-quantitative microfluidic DENV NS1 immuno-
magnetic agglutination (IMA) assay based on aggregation of magnetic nanoparticles detected
by an electronic reader (Virotrack Dengue Acute and Blubox, Blusense diagnostics). The per-
formance of the test was evaluated in samples from acute cases of DENV, chikungunya virus
(CHIKV), Zika virus (ZIKV) and Plasmodium infections and was compared against estab-
lished methods for detection of DENV NS1 antigen.
Materials and methods
Samples
A panel of 135 serum samples from travelers returning from dengue endemic countries was
analyzed in this study. The panel included 74 DENV positive samples by real time RT-PCR
including all DENV serotypes (26 DENV-1, 24 DENV-2, 15 DENV-3, 7 DENV-4, 2 non typed
DENV), 26 ZIKV positive samples by real time RT-PCR, 25 CHIKV positive samples by real
time RT-PCR, 5 malaria positive samples by thick and thin blood smear and 5 negative sam-
ples from patients with fever returning from endemic countries in which an arboviral infection
was ruled out. A summary of the samples included in the study, according to days after the
onset of symptoms and the geographical area visited by the travelers is shown in Fig 1. The
median age of travelers was 35 years old (range 6–74) and 51% were female.
Laboratory diagnosis
Acute DENV infections in travelers were diagnosed by detection of DENV RNA in serum
samples. The following methods were used for detection and/or serotyping of DENV: a com-
mercial real-time RT-PCR (LightMix Modular Dengue, TIB Molbiol, Berlin, Germany, per-
formed on LightCycler 480 II thermal cycler, Roche), an in-house real-time RT-PCR
(performed on Stratagene Mx3000P thermal cycler, Thermo Fisher Scienctific)[15] or an in-
house generic flavivirus RT-PCR [16]. RT-PCR products obtained with the later method were
then visualized in a 2% agarose gel followed by sequencing. The different methods used reflect
the availability of diagnostic assays in different periods in our laboratory: the in-house real
time RT-PCR was substituted in 2017 by the commercial assay and the generic flavivirus
RT-PCR was used for serotyping three samples. Dengue cases were classified as secondary
infections when pre-existing immunoglobulin (Ig) G against DENV (measured by PanBio
ELISA (Alere, Brisbane, Australia)) were present in the sample positive for DENV RNA [3].
The diagnosis of acute CHIKV and ZIKV infections was achieved by specific real-time
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RT-PCR (RealStar Chikungunya Virus RT-PCR kit and RealStar Zika Virus RT-PCR kit,
Altona Diagnostics GmbH, Hamburg, Germany). Malaria cases were diagnosed by thick and
thin blood smears. All samples were stored frozen at -80˚C until the DENV NS1 assays were
performed.
Tests for DENV NS1 antigen detection
The samples were tested by three different methods for detection of DENV NS1 antigen: SD
Dengue NS1 Ag ELISA (Standard Diagnostic Inc, Kyongii-Do, Korea), SD BIOLINE Dengue
Duo (Standard Diagnostic Inc, Kyongii-Do, Korea) and ViroTrack Dengue Acute (BluSense
Diagnostics, Copenhagen, Denmark). All assays were performed according to the manufactur-
er’s instructions.
SD Dengue NS1 Ag ELISA (hereinafter also referred to as ELISA) is an enzyme-linked
immunosorbent assay for the qualitative detection of NS1 antigen in human serum. SD BIO-
LINE Dengue Duo kit is a rapid immunochromatographic test (hereinafter also referred to as
immunochromatographic test or ICT) that detects both DENV NS1 antigen and antibodies
Fig 1. A. Distribution of samples by day post-onset of symptoms and final diagnosis. B. Distribution of samples by
visited region, according to the WHO regions. In 11 samples (9 positive DENV samples, one positive ZIKV sample
and one positive CHIKV sample) the country visited was not recorded.
https://doi.org/10.1371/journal.pntd.0008082.g001
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against DENV (IgM/IgG) in human serum, plasma or whole blood. ViroTrack Dengue Acute
(hereinafter also referred to as immuno-magnetic agglutination assay or IMA) is a rapid and
semi-quantitative microfluidic DENV NS1 detection method based on IMA technology[14].
The IMA test uses magnetic nanoparticles coated with a mix of monoclonal antibodies capable
of detecting NS1 from all four DENV serotypes. The test cannot differentiate between the sero-
types and returns a positive, negative, or equivocal value relative to the total amount of DENV
NS1 antigen (of one or multiple serotypes) present in the sample. The kit consists on a car-
tridge in which 30 μl of serum, plasma, whole blood or capillary blood are introduced. This
cartridge is then inserted on the reader (Blubox; BluSense Diagnostics, Copenhagen, Den-
mark), in which all the self-contained sample preparation, mixing and reading steps take
place. The reading is automatic and quantitative, and the results are obtained on the screen in
12 minutes after loading the cartridge. An overview of the main characteristics of the NS1
detection assays and the principle of the IMA technology is shown in Fig 2.
Fig 2. A. Overview of the three DENV NS1 detection methods. B. Schematic principle of the IMA technology.
Magnetic nanoparticles coated with monoclonal antibodies against DENV NS1 protein are incubated with the serum
sample. Incubation in a strong magnetic field induces NS1-mediated nanoparticle aggregation. The concentration of
NS1 in the sample is quantified by measuring the modulation of a transmitted laser light upon magnetic rotation of
nanoparticles.
https://doi.org/10.1371/journal.pntd.0008082.g002
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Statistical analysis
Sensitivity, specificity, likelihood ratios and agreement values were calculated for all methods
having molecular techniques as the gold standard. Sensitivity was calculated as: true positives/
(true positives + false negatives) and specificity as: true negatives/(true negatives + false posi-
tives). Confidence interval for sensitivity and specificity were calculated using the efficient-
score method described by Newcomb based on the procedure described by Wilson[17]. Likeli-
hood ratios indicate the increase or decrease of probability for a disease for the given test
results, and were calculated as follows: positive likelihood ratio (LR+) = sensitivity/(1-specific-
ity); negative likelihood ratio (LR-) = (1-sensitivity)/specificity) and interpreted based on Hay-
den et al[18]. Kappa coefficient, a measurement of nonrandom agreement between
measurements, was also calculated and interpreted following Landis and Koch criteria[19].
Ethics statement
This study was approved by the Ethical Comitee of Hospital Clinic (File HCB/2018/0931).
Leftovers of routine diagnostic serum samples were anonymized and stored frozen until
testing.
Results
All 135 serum samples were tested by ViroTrack Dengue Acute, 133 samples by SD Dengue
NS1 Ag ELISA and 130 samples by SD BIOLINE Dengue Duo kit (some samples could not be
tested by all methods due to insufficient sample volume).
The sensitivity, specificity, positive and negative likelihood ratios and kappa statistic values
obtained are summarized in Table 1. The results obtained for each method by type of pathogen
are shown in Table 2. Sensitivity values were higher with the ELISA (97.2%), followed by the
IMA assay (91.9%) and the ICT (68.1%). Specificity was 100% for ELISA and ICT and 98.4%
for the IMA test. One ZIKV positive sample tested positive in IMA assay. This sample was
obtained two days after the onset of the symptoms and tested positive for ZIKV and negative
for DENV and CHIKV by real-time RT-PCR. This apparent cross-reactivity was not observed
in the other 25 ZIKV positive samples tested.
For all three methods positive likelihood ratios >10 were obtained, which means that a pos-
itive result has large effect on post-test probability. For negative likelihood ratio, a ratio <0.1
was obtained both for IMA and ELISA test, which implies a large effect on post-test probabil-
ity, and a ratio of 0.3 for ICT, which means a small effect on post-test probability.
Both ELISA and IMA methods showed an almost perfect agreement with the real-time
RT-PCR gold standard according to the kappa statistic values and Landis and Koch criteria,
whereas the ICT showed a substantial agreement.
Table 1. Sensitivity, specificity, likelihood ratios and Kappa statistic results for each test with a 95% confidence interval. The gold standard used for the final diagno-
sis was the DENV RT-PCR result.
Sensitivity (%, 95% CI) Specificity (%, 95% CI) Positive Likelihood ratio Negative likelihood ratio Kappa (value, 95% CI)


















>10 0.36 (0.25–0.52) 0.7 (0.6–0,8)
1 Due to insufficient sample volume in DENV positive samples 2 SD Dengue NS1 Ag ELISA and 5 SD BIOLINE Dengue Duo could not be performed.
https://doi.org/10.1371/journal.pntd.0008082.t001
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The ELISA and the IMA assay detected all DENV-1, DENV-3 and DENV-4 positive sam-
ples included in the study. Detection rates for DENV-2 positive samples for the ELISA and
IMA assays were 95.5% and 79.2%. The tested panel included eight samples from secondary
DENV infections: seven were detected by the ELISA, six by the IMA assay and four by the
ICT.
Detection rates by days post-onset are shown on Supplementary material (S1 Table), as well
as true positive (TP), true negative (TN), false positive (FP) and false negative (FN) values for
each test (S2 Table).
Discussion
DENV infection is a frequent diagnosis in travelers returning from endemic countries[5][6].
The clinical presentation of the infection can range from asymptomatic or mild disease to a
severe syndrome. A rapid diagnostic test for dengue could contribute to better patient manage-
ment and facilitate screening of patients for arboviral surveillance programs in non-endemic
areas [20]. In the last years, local transmission of DENV and CHIKV has been documented in
several European countries, including the first autochthonous cases in Spain in 2018 [21].
Detection of DENV NS1 protein in serum of infected patients represents the principal anti-
gen-detection diagnostic method for DENV infections. A variety of both ELISAs and ICTs are
commercially available. Previous studies have observed sensitivity values of 57.7%-95.1% for
ELISA assays[7][8][9][10][11] and 40%-79.1% for immunochromatographic tests[9][11].
While the diagnostic performance of ELISA-based methods is clearly superior to that of
immunocromatography-based rapid tests, ELISA methods are more time-consuming requir-
ing 2-3h until the results are obtained. In addition, unlike rapid tests, ELISA-based assays are
not as suitable as rapid tests for screening of individual samples, given that they usually require
the use of multiple controls in each run. Thus, ELISA-based tests are not optimal for urgent
testing of individual samples and the rapid tests, which are suitable for individual sample test-
ing, do not perform sufficiently well.
Immuno-magnetic agglutination assays have been recently developed for the detection of
various biomarkers [12][22]. Their simplicity of use and rapid time to results are interesting
features for rapid diagnosis of infectious diseases. In this study, we have evaluated a novel IMA
Table 2. Positive results from the total of positive samples tested.
Panel Number of samples Positive by ViroTrack Dengue
Acute
Positive by SD Dengue NS1 Ag
ELISA
Positive by SD BIOLINE Dengue
Duo
N % N % N %
DENV 74 68 91.9 701 97.2 472 68.1
Serotype-1 26 26 100 26 100 202 83,3
Serotype-2 24 19 79.2 211 95,5 142 66.7
Serotype-3 15 15 100 15 100 11 73.3
Serotype-4 7 7 100 7 100 1 1.4
Non-typed 2 1 50 1 50 1 50
ZIKV 26 1 3.8 0 0 0 0
CHIKV 25 0 0 0 0 0 0
Malaria 5 0 0 0 0 0 0
Negative 5 0 0 0 0 0 0
1 Due to insufficient sample volume SD Dengue NS1 Ag ELISA could not be performed in 2 DENV-2 samples.
2 Due to insufficient sample volume in 2 DENV-1 samples and 3 DENV-2 samples SD BIOLINE Dengue Duo could not be performed.
https://doi.org/10.1371/journal.pntd.0008082.t002
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assay for detection of DENV NS1 antigen. We compared the IMA assay with an ELISA and
with an ICT method, considering the RT-PCR results as the gold standard. On the one hand, it
was important to compare the IMA with the ELISA, which represents the reference method
for NS1 antigen detection. On the other hand, it was specifically relevant to compare the IMA
to the ICT, as both assays represent rapid diagnostic testing and therefore would be used in the
same clinical situations.
We show that the sensitivity of the IMA (91.9%) is notably higher than the ICT (68.1%) and
only slightly lower than the ELISA (97.2%). The IMA requires the lowest amount of sample, is
very simple to perform, provides results in less than 15 minutes and offers a semi-quantitative
reading. These features make the IMA a promising candidate for rapid DENV NS1 diagnostic
testing.
The IMA technology seems to be not exempt from some limitations that have been
described for NS1 detection assays, such as the lower sensitivity for DENV-2 and for secondary
dengue infections. DENV-2 was the least detected serotype by all three methods. IMA technol-
ogy failed to detect the NS1 protein in 6 cases of confirmed DENV infection by RT-PCR,
being 5 of them DENV-2 and one non-typed DENV. Limitations in detecting DENV-2 NS1
antigen have already been addressed in other studies[7][8], obtaining a sensitivity of 63% for
DENV-2 against a 84% of sensitivity of the other three serotypes pooled[23]. A decrease in sen-
sitivity of NS1 detection kits has also been observed during DENV-2 outbreaks[24].This phe-
nomenon could be related to lower NS1 protein levels in serum in DENV-2 infections[25].
Both ELISA and IMA assays detected all DENV-4 samples, but the ICT only detected one out
of seven samples with this serotype. Low sensitivity for the detection of DENV-4 has been pre-
viously described for other NS1 assays, including the ICT that was used in our study [11].
Detection of NS1 antigen in secondary DENV infections is challenging because of lower
sensitivity, probably due to the formation of immune complexes between NS1 and pre-existing
antibodies from the previous DENV infection [25][26]. Other studies have shown a great
decrease in sensitivity when comparing primary infections to secondary infections, from 47–
71% sensitivity in primary dengue cases to 21–55% in secondary cases with ICT assays[9]. Sim-
ilar results have been reported for ELISA kits, with sensitivity values dropping from 96.1% to
67.3%[10] in secondary infections. Our study did not include a high number of secondary den-
gue cases, since the majority of our patients are travelers and DENV infections in travelers are
much more likely to be primary infections. Despite the low number of secondary dengue cases
analyzed in this study, the IMA technology seems to have better sensitivity than ICT for the
diagnosis of secondary infections. A larger study on the diagnostic performance of the IMA
technology in endemic areas would be needed to assess the usefulness of the IMA for global
dengue diagnostics.
Along with the new test, we also evaluated SD Dengue NS1 Ag ELISA and SD BIOLINE
Dengue Duo in our study. The ELISA assay had a very good performance, with results similar
to the best results obtained in other studies (sensitivity of 85–95%)[11]. Lower sensitivity val-
ues have been observed for ELISA in other studies (60–76%)[9][8]. This difference could be
explained by the number of secondary dengue infections, as well as the number of DENV-2
infections included in the studies, two factors that can severely affect the performance of the
different kits. Regarding SD BIOLINE Dengue Duo, the sensitivity observed in our study was
similar to that observed in other reports (52–66%) [9].
In this study, a sample from a patient with ZIKV infection gave a positive result for Viro-
Track Dengue Acute. The rest of the positive ZIKV samples did not give any false positive
result by ViroTrack Dengue Acute. This phenomenon of cross reactivity has been previously
described in a single sample for other rapid diagnostic tests [27]. Although it is not clear the
reasons for this cross reactivity, it seems to be a rare finding.
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The IMA test performs automatic reading of the results and quantification, providing a
robust assessment of the presence of NS1 antigen in the sample. Although some studies have
shown low inter-observer variation in the interpretation of NS1 rapid tests, differences have
also been reported and weak positive samples are more prone to be misclassified in ICTs. In
conclusion, we evaluated the utility of an IMA technology (ViroTrack Dengue Acute) for the
NS1 detection of suspected cases of DENV infection in travelers. The assay compiles several
advantages of rapid tests (short time to results, suitability for individual sample testing) and
the better performance of ELISA methods. Thus, it could represent a valuable tool for the diag-
nosis of acute DENV infections.
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Muñoz.
Resources: Miguel J. Martı́nez.
Supervision: Miguel J. Martı́nez.
Writing – original draft: Izaskun Alejo-Cancho.
Writing – review & editing: Izaskun Alejo-Cancho, Miguel J. Martı́nez.
References
1. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Prim.
Macmillan Publishers Limited; 2016; 2: 1–26. https://doi.org/10.1038/nrdp.2016.55 PMID: 27534439
2. Soo KM, Khalid B, Ching SM, Chee HY. Meta-analysis of dengue severity during infection by different
dengue virus serotypes in primary and secondary infections. PLoS One. 2016; 11: 4–14. https://doi.org/
10.1371/journal.pone.0154760 PMID: 27213782
3. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention, and control. Spec
Program Res Train Trop Dis. 2009; x, 147. doi: WHO/HTM/NTD/DEN/2009.1
Evaluation of a novel dengue NS1 antigen detection assay
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008082 February 18, 2020 9 / 11
4. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and
burden of dengue. Nature. Nature Publishing Group; 2013; 496: 504–507. https://doi.org/10.1038/
nature12060 PMID: 23563266
5. Schlagenhauf P, Weld L, Goorhuis A, Gautret P, Weber R, Sonnenburg F Von, et al. Travel-associated
infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data,
and evaluation of the eff ect of the pre-travel consultation. 2013; 55–64. https://doi.org/10.1016/S1473-
3099(14)71000-X
6. Leder K, Torresi J, Libman MD, Cramer JP, Castelli F, Schlagenhauf P, et al. GeoSentinel surveillance
of illness in returned travelers, 2007–2011. Ann Intern Med. 2013; 158: 456–468. https://doi.org/10.
7326/0003-4819-158-6-201303190-00005 PMID: 23552375
7. Duong V, Ly S, Try P, Tuiskunen A, Ong S, Chroeung N, et al. Clinical and virological factors influencing
the performance of a ns1 antigen-capture assay and potential use as a marker of dengue disease
severity. PLoS Negl Trop Dis. 2011; 5. https://doi.org/10.1371/journal.pntd.0001244 PMID: 21811645
8. Wang SM, Sekaran SD. Evaluation of a commercial SD dengue virus NS1 antigen capture enzyme-
linked immunosorbent assay kit for early diagnosis of dengue virus infection. J Clin Microbiol. 2010; 48:
2793–2797. https://doi.org/10.1128/JCM.02142-09 PMID: 20573879
9. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, et al. Evaluation of Commer-
cially Available Diagnostic Tests for the Detection of Dengue Virus NS1 Antigen and Anti-Dengue Virus
IgM Antibody. PLoS Negl Trop Dis. 2014; 8. https://doi.org/10.1371/journal.pntd.0003171 PMID:
25330157
10. Hermann LL, Thaisomboonsuk B, Poolpanichupatam Y, Jarman RG, Kalayanarooj S, Nisalak A, et al.
Evaluation of a Dengue NS1 Antigen Detection Assay Sensitivity and Specificity for the Diagnosis of
Acute Dengue Virus Infection. PLoS Negl Trop Dis. 2014; 8: 1–8. https://doi.org/10.1371/journal.pntd.
0003193 PMID: 25275493
11. Pal S, Dauner AL, Mitra I, Forshey BM, Garcia P, Morrison AC, et al. Evaluation of dengue ns1 antigen
rapid tests and elisa kits using clinical samples. PLoS One. 2014; 9. https://doi.org/10.1371/journal.
pone.0113411 PMID: 25412170
12. Uddin R, Burger R, Donolato M, Fock J, Creagh M, Hansen MF, et al. Lab-on-a-disc agglutination
assay for protein detection by optomagnetic readout and optical imaging using nano- and micro-sized
magnetic beads. Biosens Bioelectron. Elsevier; 2016; 85: 351–357. https://doi.org/10.1016/j.bios.2016.
05.023 PMID: 27183287
13. Park H, Hwang MP, Lee KH. Immunomagnetic nanoparticle-based assays for detection of biomarkers.
Int J Nanomedicine. 2013; 8: 4543–4552. https://doi.org/10.2147/IJN.S51893 PMID: 24285924
14. Antunes P, Watterson D, Parmvi M, Burger R, Boisen A, Young P, et al. Quantification of NS1 dengue
biomarker in serum via optomagnetic nanocluster detection. Sci Rep. Nature Publishing Group; 2015;
5: 1–10. https://doi.org/10.1038/srep16145 PMID: 26536916
15. Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses in a fourplex real-
time reverse transcriptase PCR assay. J Clin Microbiol. 2005; 43: 4977–4983. https://doi.org/10.1128/
JCM.43.10.4977-4983.2005 PMID: 16207951
16. Moureau G, Temmam S, Gonzalez JP, Charrel RN, Grard G, de Lamballerie X. A real-time RT-PCR
method for the universal detection and identification of flaviviruses. Vector Borne Zoonotic Dis. 2007; 7:
467–477. https://doi.org/10.1089/vbz.2007.0206 PMID: 18020965
17. Newcombe RG. IMPROVED CONFIDENCE INTERVALS FOR THE DIFFERENCE BETWEEN BINO-
MIAL PROPORTIONS BASED ON PAIRED DATA. 1998;2650.
18. Hayden SR, Brown MD. Likelihood ratio: A powerful tool for incorporating the results of a diagnostic test
into clinical decisionmaking. Ann Emerg Med. 1999; 33: 575–580. https://doi.org/10.1016/s0196-0644
(99)70346-x PMID: 10216335
19. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data Published by:
International Biometric Society Stable URL: http://www.jstor.org/stable/2529310. Society. 2008;33:
159–174. https://doi.org/10.2307/2529310
20. Tomasello D, Schlagenhauf P. Chikungunya and dengue autochthonous cases in Europe, 2007–2012.
Travel Med Infect Dis. Elsevier Ltd; 2013; 11: 274–284. https://doi.org/10.1016/j.tmaid.2013.07.006
PMID: 23962447
21. European centre for disease prevention and control. Local transmission of dengue fever in France and
Spain—2018.
22. Mezger A, Fock J, Antunes P,Østerberg FW, Boisen A, Nilsson M, et al. Scalable DNA-Based Magnetic
Nanoparticle Agglutination Assay for Bacterial Detection in Patient Samples. ACS Nano. 2015; 9:
7374–7382. https://doi.org/10.1021/acsnano.5b02379 PMID: 26166357
Evaluation of a novel dengue NS1 antigen detection assay
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008082 February 18, 2020 10 / 11
23. Guzman MG, Jaenisch T, Gaczkowski R, Thi V, Hang T, Sekaran SD, et al. Multi-Country Evaluation of
the Sensitivity and Specificity of Two Commercially-Available NS1 ELISA Assays for Dengue Diagno-
sis. 2010; 4: 2–11. https://doi.org/10.1371/journal.pntd.0000811 PMID: 20824173
24. Felix AC, Centrone CDC, Villas-boas L, Maria C, Martelli T. Low Sensitivity of NS1 Protein Tests Evi-
denced during a Dengue Type 2 Virus Outbreak in Santos, Brazil, in 2010. 2012; 19: 1972–1976.
https://doi.org/10.1128/CVI.00535-12 PMID: 23100478
25. Duyen HTL, Ngoc T V, Ha DT, Hang VTT, Kieu NTT, Young PR, et al. Kinetics of Plasma Viremia and
Soluble Nonstructural Protein 1 Concentrations in Dengue: Differential Effects According to Serotype
and Immune Status. 2011; 203. https://doi.org/10.1093/infdis/jir014 PMID: 21335562
26. Koraka P, Burghoorn-maas CP, Falconar A, Setiati TE, Djamiatun K, Groen J, et al. Detection of
Immune-Complex-Dissociated Nonstructural-1 Antigen in Patients with Acute Dengue Virus Infections.
2003; 41: 4154–4159. https://doi.org/10.1128/JCM.41.9.4154-4159.2003 PMID: 12958240
27. Gyurech D, Schilling J, Schmidt-Chanasit J, Cassinotti P, Kaeppeli F, Dobec M. False positive dengue
NS1 antigen test in a traveller with an acute Zika virus infection imported into Switzerland. Swiss Med
Wkly. 2016; 146: w14296. https://doi.org/10.4414/smw.2016.14296 PMID: 26859285
Evaluation of a novel dengue NS1 antigen detection assay
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008082 February 18, 2020 11 / 11
